ChemoCentryx’s Avacopan May Need Another Trial After Tepid Advisory Committee Vote

 
• By Sarah Karlin-Smith
  
ChemoCentryx’s avacopan may need a second Phase III trial to get FDA approval.

More from US FDA Performance Tracker

More from Regulatory Trackers